Publications
5891 Results
- Journal / Conference
- Blood 126(23):908; American Society of Hematology Annual Meeting (Dec 5-8, 2015, Orlando, FL), oral;
- Year
- 2015
- Research Committee(s)
- Leukemia
- Study Number(s)
- S1117
Additional analyses of a randomized phase II study of azacitidine combined with lenalidomide or with vorinostat vs. azacitidine monotherapy in higher-risk myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML): North American Intergroup Study SWOG S1117
- Journal / Conference
- American College of Surgeons Bulletin Dec;100(12):49-50
- Year
- 2015
- Research Committee(s)
- Palliative Care
- PMID
- PMID26749971
- Study Number(s)
- S1316
Prospective comparative effectiveness trial for malignant bowel obstruction: SWOG S1316
- Journal / Conference
- Seminars in Oncology, Oct;42(5):679-680
- Year
- 2015
- Research Committee(s)
- Cancer Care Delivery
- PMID
- PMID26433548
Progress and infrastructure for improved patient outcomes of the National Cancer Institute Network Groups [Introduction to Issue, "The NCI Network Groups"]
- Journal / Conference
- Journal of Thoracic Oncology 10(9): S141 (Suppl 2, MTE 02); World Conference on Lung Cancer (WCLC), oral;
- Year
- 2015
- Research Committee(s)
- Lung
- Study Number(s)
- S1400
Patients, investigators and pharmaceuticals working together to accelerate research and access: the lung cancer master protocol (Lung-MAP) clinical trial
- Journal / Conference
- Journal of Thoracic Oncology 10(9):S80 (Suppl 2, abst ED07.03); World Conference on Lung Cancer (WCLC) (September 6-9, 2015, Denver, CO), oral;
- Year
- 2015
- Research Committee(s)
- Lung
- Study Number(s)
- S1400
Lung master protocol in squamous cell lung Cancer (Lung-MAP, S1400)
- Journal / Conference
- Blood 126(23):6;American Society of Hematology Annual Meeting (Dec 5-8, 2015, Orlando, FL), oral;
- Year
- 2015
- Research Committee(s)
- Leukemia
- Study Number(s)
- CTSU/C10603
The multi-kinase inhibitor midostaurin (M) prolongs survival compared with placebo (P) in combination with daunorubicin (D)/cytarabine (C) induction (ind), high-dose C consolidation (consol), and as maintenance (maint) therapy in newly diagnosed acute myeloid leukemia (AML) patients (pts) age 18-60 with FLT3 mutations (muts): an international prospective randomized (rand) P-controlled double-blind trial (CALGB 10603/RATIFY [Alliance])
- Journal / Conference
- Chinese Clinical Oncology Sep;4(3):36
- Year
- 2015
- Research Committee(s)
- Lung
- PMID
- PMID26408303
- PMC
- PMCID n/a
- Study Number(s)
- S1400
Lung-MAP--framework, overview, and design principles
- Journal / Conference
- Breast Cancer Research, Oct 1;17(1):133
- Year
- 2015
- Research Committee(s)
- Breast
- PMID
- PMID26429296
- PMC
- PMC4589954
- Study Number(s)
- N9831
The relationship between quantitative human epidermal growth factor receptor 2 gene expression by the 21-gene reverse transcriptase polymerase chain reaction assay and adjuvant trastuzumab benefit in Alliance N9831
- Journal / Conference
- JAMA Oncology, Jun;1(3):321-322
- Year
- 2015
- Research Committee(s)
- Cancer Control
- PMID
- PMID26181178
- PMC
- PMC n/a
- Study Number(s)
- SWOG-9217
Effect of 5a-reductase inhibitor use on mortality from prostate cancer [Editorial/Commentary]
- Journal / Conference
- Journal of the National Cancer Institute 108(2). pii: djv324. doi: 10.1093/jnci/djv324.
- Year
- 2015
- Research Committee(s)
- Cancer Care Delivery
- PMID
- PMID26714555
- PMC
- PMC5964887